13therapeutics Receives Patent Covering Three Additional Compounds for the Treatment of Inflammatory and Autoimmune Disorders

13therapeutics announced it has been issued a patent on three additional peptide therapeutics for the treatment of inflammatory and autoimmune disorders. The patent covers the Composition of Matter of the Peptides and the Method of Use of Inhibiting TLR-induced Inflammation.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“We are very pleased to have been issued a patent for these three additional compounds”, said Dr. Steven Hefeneider, President and Chief Scientific Officer. “Combined with our other compounds, we now have a broad portfolio of potential therapeutics."

Portland, OR (PRWEB) January 30, 2013

13therapeutics announced it has been issued a patent on three additional peptide therapeutics. The compounds, named P16, P17, and P18, are for the treatment of inflammatory and autoimmune disorders. The patent covers the Composition of Matter of the Peptides and the Method of Use of Inhibiting TLR-induced Inflammation.

TLRs (Toll-like Receptors) are a class of proteins that play a key role in the innate immune system. TLRs are cell receptors that recognize pathogens (virus, bacteria, fungus) that have penetrated the body’s physical barrier such as skin or intestinal mucosa. When TLRs and pathogens interact, an inflammatory response is triggered designed to eliminate or contain the pathogen. Sometimes this mechanism gets out of control triggering autoimmune diseases such as Rheumatoid Arthritis, Lupus, Crohn’s disease, or chronic inflammatory diseases such as Otitis Media (ear infection/fluid) or Uveitis. The peptides developed by 13therapeutics can potentially reduce inflammation and reset the immune system by inhibiting a specific TLR response.

P16, P17 and P18 bring the company’s number of patented peptides to five. P13 is being advanced for the treatment of the Hearing Loss associated with Otits Media, Noise insults, and Age. P7 is being developed for the treatment of viral induced inflammation, such as the pulmonary inflammation seen in RSV and Influenza pneumonia. P16 is being developed for the treatment of acute and chronic bacterial induced inflammatory diseases, such as the pulmonary inflammation caused by Pseudomonas Aeruginosa and its accompanying complications in patients with Cystic Fibrosis.

“We are very pleased to have been issued a patent for these three additional compounds”, said Dr. Steven Hefeneider, 13therapeutics President and Chief Scientific Officer. “Combined with our other compounds that have patents pending, this gives us a broad portfolio of potential therapeutics.”

About 13therapeutics

13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. Founded in 2009, the Portland, Oregon-based company is a spin-out from the Oregon Health and Science University (OHSU). The management team and research scientists of 13therapeutics are veterans of bioscience, research and technology.


Contact